NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: VALIANTLAB · data 2026-10-30
Valiant Laboratories Ltd.
In plain words
Price: 9.2% below its 52-week high of ₹141.38.
Delivery: 71.1% of traded shares were kept for delivery over the last 10 sessions, against 70.5% over the last 60.
Latest results: a net profit of ₹21 cr for the quarter ended Jun 2026 (+1059.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹306 cr |
| Net profit (last 12 months) | ₹16 cr |
| Sales growth, 3 years (yearly) | -10.7% |
| Profit growth, 3 years (yearly) | — |
Latest results in brief (Q1 FY27)
VALIANTLAB Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹115.29 crore, up 146.2% YoY and up 25.3% QoQ.
Net profit was ₹21.1 crore, up 1,059.3% YoY and up 1,098.9% QoQ.
Operating margin was 25.4% (5.1% a year ago).
EPS was ₹3.89, up 1,044.1% YoY and up 1,115.6% QoQ.
VALIANTLAB के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹115.29 करोड़; पिछले साल की तुलना में 146.2% की बढ़त, पिछली तिमाही की तुलना में 25.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹21.1 करोड़; पिछले साल की तुलना में 1,059.3% की बढ़त, पिछली तिमाही की तुलना में 1,098.9% की बढ़त।
ऑपरेटिंग मार्जिन: 25.4% (एक साल पहले 5.1%)।
EPS: ₹3.89; पिछले साल की तुलना में 1,044.1% की बढ़त, पिछली तिमाही की तुलना में 1,115.6% की बढ़त।
VALIANTLABના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹115.29 કરોડ; ગયા વર્ષની સરખામણીએ 146.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 25.3% વધારો.
ચોખ્ખો નફો: ₹21.1 કરોડ; ગયા વર્ષની સરખામણીએ 1,059.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1,098.9% વધારો.
ઓપરેટિંગ માર્જિન: 25.4% (એક વર્ષ પહેલાં 5.1%).
EPS: ₹3.89; ગયા વર્ષની સરખામણીએ 1,044.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1,115.6% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Rights
- 10 Aug 26Results Q1 FY27 results: profit +1059.3% YoY +10.2% next session
- 14 May 26Results Q4 FY26 results: profit +151.4% YoY -2.8% next session
- 11 Feb 26Results Q3 FY26 results: turned to loss vs a year ago -6.2% next session
- 11 Nov 25Results Q2 FY26 results: turned to profit vs a year ago -2.0% next session
- 8 Aug 25Results Q1 FY26 results: turned to profit vs a year ago 0.0% next session
- 18 Jul 25Rights Rights issue 1:4 · premium ₹65 (ex-date) -16.2% next session
- 30 May 25Results Q4 FY25 results: turned to profit vs a year ago +4.0% next session
- 20 May 25Results Results board meeting -0.8% next session
- 7 Feb 25Results Q3 FY25 results: turned to profit vs a year ago -3.9% next session
- 12 Nov 24Results Q2 FY25 results: turned to loss vs a year ago -4.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹115 cr | ₹21 cr | +1059.3% | 25.4% | 3.89 |
| Mar 2026 | ₹92 cr | ₹2 cr | +151.4% | 5.2% | 0.32 |
| Dec 2025 | ₹52 cr | ₹-7 cr | -400.4% | -1.7% | -1.3 |
| Sept 2025 | ₹46 cr | ₹0 cr | — | 0.2% | 0.04 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 74.94% | 74.94% | 74.94% | 74.94% |
| Foreign institutions (FII) | 0.07% | 0.00% | 0.20% | 0.01% |
| Domestic institutions (DII) | 0.08% | 0.00% | 0.00% | 0.00% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 10.57% | 10.32% | 10.31% | 10.04% |
| Number of shareholders | 14,618 | 14,341 | 14,657 | 14,910 |
Common questions
What was Valiant Laboratories Ltd.'s latest quarterly profit?
Valiant Laboratories Ltd. reported a net profit of ₹21 cr for the quarter ended Jun 2026 (+1059.3% on the same quarter a year earlier), on revenue of ₹115 cr.
How much do promoters hold in Valiant Laboratories Ltd.?
Promoters held 74.94% of Valiant Laboratories Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Valiant Laboratories Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.15.
What is Valiant Laboratories Ltd.'s P/E ratio?
About 43.5, based on the last 12 months' earnings and a price of ₹128.4 (data 2026-10-30).
What is the 52-week high and low of Valiant Laboratories Ltd.?
The 52-week high is ₹141.38 and the 52-week low is ₹49.51.
Similar companies
Anuh Pharma Limited (ANUHPHR) · Kilitch Drugs (India) Limited (KILITCH) · Hexagon Nutrition Limited (HEXAGON) · Amanta Healthcare Limited (AMANTA) · Wanbury Limited (WANBURY)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open VALIANTLAB in NSE Scanner →